Filgotinib Shows Positive Results in Axial SpA Phase 3 Trial
July 28, 2025
Alfasigma plans to submit data from the OLINGUITO Phase 3 clinical trial to European Medicines Agency (EMA) and UK’s Medicines Healthcare products Regulatory Agency (MHRA)